{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Grade 1-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Grade 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"Adverse events (AE) that are classified as either possibly, probably, or definitely related to study treatment according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE version 3.0). The maximum grade for each type of AE will be recorded for each patient. Grade refers to the severity of the AE.\n\nGrade 1: Mild AE, Grade 2: Moderate AE, Grade 3: Severe AE, Grade 4: Life-threatening or disabling AE, Grade 5: Death related AE\n\nAdverse events will be assessed using NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0.","groups":[{"description":"Bortezomib IV on days 1, 8, and 15, oral cyclophosphamide and oral dexamethasone once daily on days 1, 8, 15, and 22.","id":"OG000","title":"Bortez/Cyc/Dex"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Duration on treatment (up to 12 cycles/months)","title":"Number of Participants With Treatment Related Adverse Events.","type":"SECONDARY","unitOfMeasure":"participants"}